Spinraza® (nusinersen)

Covered: Spinraza (nusinersen) is covered for pediatric and adult SMA when strict genetic, SMN2 copy, baseline motor-assessment, prescriber, and documentation criteria are met; prior Zolgensma (onasemnogene abeparvovec) recipients are excluded and patients on Evrysdi (risdiplam) must discontinue it. Key requirements: initial approval requires documented bi-allelic SMN1 pathogenic variants, two or three SMN2 copies (or four copies with symptomatic Types 1–3), a baseline motor score from specified scales, prescription/consultation by an SMA/neuromuscular specialist, intrathecal 12 mg dosing per the 4‑dose loading then q4‑month maintenance schedule (initial approval 3 months), and renewals require ≥4 months since last dose plus documented clinical improvement or continued benefit (renewal 4 months).

"Spinraza is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients."